89bio
Updated January 2022.
86%
Employees say this is a great place to work
Company Overview
About The Company
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG.
COMPANY SIZE
40 U.S.-based Employees
(Small)
Industry
Biotechnology & Pharmaceuticals
HQ Location
San Francisco, CA, US
Interested in a career at 89bio, or just want to know more?
To discover what sets 89bio apart and explore relevant career opportunities, take a look at their website.
Employee Demographics
Tenure
Company Culture at 89bio
The employee experience below at 89bio, compared to a typical company.
Learn More86% of employees at 89bio say it is a great place to work compared to 57% of employees at a typical U.S.-based company.
97%
Management is honest and ethical in its business practices.
97%
People here are willing to give extra to get the job done.
95%
People here are given a lot of responsibility.
95%
People here are paid fairly for the work they do.
95%
When I look at what we accomplish, I feel a sense of pride.
Why Work at 89bio?
See what employees say about what makes 89bio a great workplace. These words are drawn from employee comments on the Trust Index™ survey.
CONNECT